



PLEASE RELEASE

February 21, 2019.  
Fuji Pharma Co.,Ltd.

## **Acquiring Manufacturing Approval for Our Products in Thailand**

OLIC (Thailand) Limited, a subsidiary of Thailand (hereinafter "OLIC "), announced that the following products have been approved for the production of Iopark 300 Injection and Iopark 350 Injection in Thailand on February 15, 2019.

This is a non-ionic contrast media that has served as our mainstay product since its launch in Japan in 2001. With the approval of this product in Thailand, our group was the first to obtain manufacturing approval for our drug overseas.

In the Thai market, in June 2018, we signed a contract with APO PLUS STATION (THAILAND) CO., LTD., (Address: Bangkok, Thailand, President: Suthas Thongprasert) to support the marketing of pharmaceuticals. In October 2018, we launched our branded pharmaceutical sales department in OLIC, and we are steadily making preparations for the sale of pharmaceuticals. Starting with this product, we will continue our efforts to launch our products in Thailand and other ASEAN countries.

Products approved for production in Thailand

Product name	Name of the original product
IOPAQUE 300 INJECTION	OMNIPAQUE 300 MGI/ML
IOPAQUE 350 INJECTION	OMNIPAQUE 350 MGI/ML